In vivo antitumour efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumour xenograft models including several lung and gastric tumours

European Journal of Cancer

Volumn 37, Issue 11, 2001, Pages 1419-1428

  Sato, Y ^a   Kashimoto, S ^a   MacDonald, J R ^b   Nakano, K ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

6 Hydroxymethylacylfulvene; Human gastric tumours; Human lung tumours; In vivo antitumour efficacy; MGI 114

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; PACLITAXEL; VINDESINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; COLON ADENOCARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG TUMOR; MELANOMA; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; STOMACH CARCINOMA; STOMACH TUMOR; TUMOR MODEL; TUMOR REGRESSION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; COLONIC NEOPLASMS; HUMANS; LUNG NEOPLASMS; MELANOMA; MICE; MICE, NUDE; SESQUITERPENES; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034961022     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00135-6     Document Type: Conference Paper

References (20)

1. Efficacy of acylfulvene illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: Retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells
2. Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells
3. (Hydroxymethyl)acylfulvene: An illudin derivative with superior antitumor properties
4. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents
5. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S
6. Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-Hydroxymethylacyllfulvene (HMAF, MGI 114)
7. Cancer statistics, 1998
8. General mortality
9. Studies on KW-2307 (navelbine) (III), in vivo combination effect with cisplatin (CDDP)
10. Studies on AT-3510, a novel cyclopropapyrroloindole (CPI) analogue (3). As a new antitumor agent against human tumor cells
11. Antimetastatic activity of a newly synthesized compound Am555S (TAC-101) and tumor growth inhibition when used in combination with other chemotherapeutic agents
12. Potent antitumor effect of DX-8951f, a new camptotecin derivative, on human tumor xenografts in nude mice
13. Antitumor activity of combination treatment combining gemcitabine with cisplatin or vindesine against human lung cancer xenografted in nude mice
14. Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice
15. Efficacy of MGI 114 (6-hydroxymethylacylfunvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft
16. Anti-tumor efficacy of paclitaxel against human lung cancer xenografts
17. Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF)
18. Evaluation of the efficiency of targeting of antitumor drugs: Simulation analysis based on pharmacokinetic/pharmacodynamic considerations
19. Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines
20. Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF)